



May 28, 2013

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400 001.

The National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.

Dear Sirs,

Please be informed that the Board of Directors of the Company in its meeting held today -

- (i) accorded its approval to consolidate the Company's **Pharmaceutical Segment** under two separate verticals, comprising *inter alia* of (i) Active Pharmaceuticals Ingredients, Solid Dosage Form, Radio Pharmaceuticals, Allergic Extracts, Sterile Injectable and Ointment, Cream and Liquid businesses ("**Pharma Business**") and (ii) Drug Discovery Businesses ("**Drug Discovery business**"), subject to all necessary approvals/ consents/ permissions and sanctions.
- (ii) constituted a committee to decide the modalities of consolidating the **Pharma Business** and the **Drug Discovery Business** under two separate subsidiaries of the Company and explore, identify and implement the options and opportunities of raising money by listing the **Pharma business** for its growth and reduction of overall consolidated debt of the Company.

You are requested to kindly take the aforesaid information on your record.

Thanking you,

Yours faithfully,

For **Jubilant Life Sciences Limited**

Lalit Jain
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000

Regd Office:
Bhartiagram, Gajraula
Distt. Jyotiba Phoolay Nagar- 244 223
UP, India